<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678691</url>
  </required_header>
  <id_info>
    <org_study_id>ArmoFibro-001</org_study_id>
    <nct_id>NCT00678691</nct_id>
    <nct_alias>NCT00568919</nct_alias>
  </id_info>
  <brief_title>An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Armodafinil (NuvigilTM) is an isomer of a drug currently approved by the FDA for the
      treatment of fatigue secondary to narcolepsy, sleep apnea, and shift work sleep disorder
      called modafinil (ProvigilTM). There is considerable off label evidence for modafinil's
      ability to reduce fatigue related to multiple sclerosis, Parkinson's disease, cancer related
      fatigue, and depression related fatigue. There are preclinical studies showing that modafinil
      can alleviate fatigue secondary to medication side effects (diazepam, chlorpromazine). This
      multi-layered evidence base suggests that modafinil may be able to alleviate fatigue
      regardless of medical illness. Armodafinil now has four completed Phase III FDA regulatory
      studies revealing that it is well tolerated and effective for fatigue associated with
      obstructive sleep apnea (Effects of Armodafinil in the Treatment of Residual Excessive
      Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome: A 12-Week, Multicenter,
      Double-Blind, Randomized,Placebo-Controlled Study in nCPAP-Adherent Adults. Thomas Roth et
      al. Clinical Therapeutics/Volume 28, Number 5, 2006), shift work sleep disorder, and
      narcolepsy. Armodafinil is not yet FDA approved. It is felt to be a cleaner, safer, more
      potent isomer. Theoretically, fatigue is interpreted and possibly dictated centrally and
      armodafinil's proposed mechanism (similar to that of modafinil) of elevating central
      histamine activity may allow the brain to interpret a lower fatigue state, thus allowing
      patients to function better during the day with less peripheral fatigue.

      Fibromyalgia (FM) is an illness that may involve medical, rheumatological, autoimmune, sleep,
      endocrine and psychiatric pathology. It is a syndrome of recurrent pain at trigger points.
      Greater than 90% of these patients will report fatigue as a key symptom as well. There are
      several investigation lines into the treatment of FM induced pain. Exercise, behavioral
      therapy, amitryptiline, duloxetine, tramadol, sodium oxybate all have randomized trials and
      almost all focus on pain. There are very few studies, if any, that look at FM induced fatigue
      which certainly ads to FM patients' daily incapacity and lowered productivity/quality of
      life.

      Armodafinil is a drug with minimal adverse effects (headache, insomnia, GI distress, anxiety,
      dry mouth, dizziness and an assumed low level addiction which is comparable to modafinil)
      which is well tolerated in current regulatory studies. It may have a safer tolerability
      profile than the FM medications noted above. As modafinil is often studied and often added as
      an augmentation agent to patients' regimens who suffer from fatigue in other medical
      illnesses, the authors feel that armodafinil would also be effective in this population. The
      authors wish to conduct a study to determine if armodafinil is safe and tolerable in the
      treatment of FM induced fatigue. This initial controlled study may allow for continued
      regulatory studies with this product in FM subjects. We propose a double-blind placebo
      controlled study to determine if armodafinil is safe and effective in reversing FM induced
      fatigue.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Fatigue Inventory</measure>
    <time_frame>8 weeks</time_frame>
    <description>This scale measures overall fatigue due to medical illness. range is 0-80 with 80 being severe fatigue</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Fibromyalgia, Primary</condition>
  <arm_group>
    <arm_group_label>A,1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>armodafinil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A,2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>armodafinil</intervention_name>
    <description>50-250mg/d</description>
    <arm_group_label>A,1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>A,2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If possible, 60 subjects will be included in this study.

          -  All males/females of any race are eligible if aged between 18 and 65 and

          -  Subjects must speak English and have capacity to receive and utilize informed consent

          -  Agree to use barrier method contraception or are infertile x2 years due to medical
             condition or surgery

          -  Have been formally diagnosed by a Board Certified Rheumatologist using the ACR 1990
             research criteria for fibromylagia

          -  Report that fatigue, in addition to FM pain is a key distressing symptom of their FM

          -  Have a score of &gt;4 on the Brief Fatigue Inventory (BFI)

          -  Women of child bearing potential must agree to use barrier contraception as
             armodafinil may decrease the effectiveness of oral contraceptives

        Exclusion Criteria:

          -  Exclusion: Subjects cannot

          -  Be pregnant or be attempting to conceive at present (urine bHCG must be negative)

          -  Have an active substance abuse problem with last use within the past 180 days (outside
             of nicotine)

          -  Use other stimulating medication ie stimulants, caffeine products (this refers to OTC
             stimulants OR patients clinically tolerant to and withdrawing from caffeinated
             beverages, bupropion, desipramine, etc UNLESS said drug has been in steady dosing for
             &gt;4 weeks

          -  Have a known medical condition outside of FM that causes fatigue (i.e. obstructive
             apnea, hypothyroidism, depression, etc)

          -  Have a known medical condition or other medication use that relatively contraindicates
             armodafinil use (ie substance abuse, sensitivity to armodafinil, known cardiac
             abnormalities of left ventricular hypertrophy, recent MI, mitral valve prolapse
             dependent on stimulant use, history of psychosis

          -  Has a prior history of modafinil use and failure

          -  Be receiving daytime sedating medication with clear chronological impact on fatigue
             UNLESS fatigue predates sedating medication or said medication has been steadily dosed
             &gt; 4 weeks

          -  Medications that induce/inhibit p450 3A4 as they may alter armodafinil plasma levels,
             and vica versa
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2008</study_first_submitted>
  <study_first_submitted_qc>May 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2008</study_first_posted>
  <results_first_submitted>September 6, 2012</results_first_submitted>
  <results_first_submitted_qc>December 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 18, 2014</results_first_posted>
  <last_update_submitted>December 9, 2014</last_update_submitted>
  <last_update_submitted_qc>December 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York - Upstate Medical University</investigator_affiliation>
    <investigator_full_name>Thomas L. Schwartz, M.D.</investigator_full_name>
    <investigator_title>Assoc Professor</investigator_title>
  </responsible_party>
  <keyword>fibromyalgia</keyword>
  <keyword>fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were easily recruited and screened for study entry</recruitment_details>
      <pre_assignment_details>Subjects were exluded after informed consent if medical confounding variables or safety variables were found</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A,1 Armodafinil Study Drug 50-250mg Flexible Dose</title>
          <description>armodafinil</description>
        </group>
        <group group_id="P2">
          <title>A,2 Matching Placebo</title>
          <description>placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A,1 Armodafinil Study Drug</title>
          <description>armodafinil</description>
        </group>
        <group group_id="B2">
          <title>A,2 Matching Placebo</title>
          <description>placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="4"/>
                    <measurement group_id="B2" value="47" spread="4"/>
                    <measurement group_id="B3" value="49" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brief Fatigue Inventory</title>
        <description>This scale measures overall fatigue due to medical illness. range is 0-80 with 80 being severe fatigue</description>
        <time_frame>8 weeks</time_frame>
        <population>last observation carried forward after power analysis calculated</population>
        <group_list>
          <group group_id="O1">
            <title>A,1 Armodafinil Study Drug</title>
            <description>armodafinil</description>
          </group>
          <group group_id="O2">
            <title>A,2 Matching Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Fatigue Inventory</title>
          <description>This scale measures overall fatigue due to medical illness. range is 0-80 with 80 being severe fatigue</description>
          <population>last observation carried forward after power analysis calculated</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread=".149"/>
                    <measurement group_id="O2" value="4.29" spread=".144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Authors expected armodafinal to work better than placebo reducing BFI scale scores by 30%. A piecewise statistical model was used to compare baseline scores against those over through week 8. Piecewise results for between group differences for BFI Scores: P=.390 (baseline through week 5), p=.775 (week 5 – week 8).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>all p-values come from one model analysis and are therefore included in free text as such</p_value_desc>
            <method>piecewise model</method>
            <method_desc>A piecewise statistical model results for between group differences: P=.390 (baseline through week 5), p=.775 (week 5 – week 8</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A,1 Armodafinil Study Drug</title>
          <description>armodafinil</description>
        </group>
        <group group_id="E2">
          <title>A,2 Matching Placebo</title>
          <description>placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Poor Concentration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Schwartz</name_or_title>
      <organization>SUNY Upstate Medical University</organization>
      <phone>3154643166</phone>
      <email>schwartt@upstate.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

